Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Lymphoma highlights at ASCO 2022

Stephen Ansell • 4 Jun 2022
ASCO 2022
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Dacarbazine Doxorubicin Vinblastine

Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives his highlights in the field of lymphoma presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the progression-free survival (PFS) results of first-line brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients. Prof. Ansell additionally talks on racial and socioeconomic disparities in lymphoma care, which can be especially pronounced with the advent of novel and expensive therapies. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.

More from Stephen Ansell

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
1:03
What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell • 11 Dec 2023
0:51
Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell • 11 Dec 2023
1:21
Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals